{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:33:36Z","timestamp":1790948016816,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18-01949"],"award-info":[{"award-number":["PI18-01949"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018689","name":"Spanish Clinical Research network","doi-asserted-by":"publisher","award":["PT13\/0002\/0031"],"award-info":[{"award-number":["PT13\/0002\/0031"]}],"id":[{"id":"10.13039\/501100018689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018689","name":"Spanish Clinical Research network","doi-asserted-by":"publisher","award":["PT17\/0017\/0003"],"award-info":[{"award-number":["PT17\/0017\/0003"]}],"id":[{"id":"10.13039\/501100018689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["CP18\/00073"],"award-info":[{"award-number":["CP18\/00073"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrence of Clostridioides difficile infection (CDI) is frequent, particularly in patients requiring subsequent systemic antibiotics. Observational studies suggest that secondary prophylaxis with oral vancomycin (SPV) may reduce recurrence risk, but randomized evidence remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PREVAN (NCT05320068) was a phase III, double-blind, placebo-controlled randomized clinical trial conducted at a tertiary hospital in Spain. Adults with documented CDI within the previous 180\u2005days who required hospitalization and systemic antibiotics were randomized (2:1) to receive oral vancomycin (125\u2005mg every 6\u2005h) or placebo for 10\u2005days, stratified by type of index CDI episode. Primary endpoints were CDI recurrence within 60\u2005days after end of therapy and CDI recurrence-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one patients were enrolled (14 SPV; 7 placebo). Mean age was 73.5\u2005years and 76.7% had malignancy and\/or immunosuppression. CDI recurrence occurred in 5 patients (23.8%): 2 (14.3%) in the SPV group and 3 (42.9%) in the placebo group (P\u200a=\u200a0.30). CDI recurrence-free survival at 60\u2005days was 83% (95% CI 48\u201395) with SPV versus 42% (95% CI 6\u201377) with placebo (log-rank P\u200a=\u200a0.09). No treatment-related serious adverse events were observed; one mild diarrhoeal event occurred in a placebo-treated patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In high-risk patients with recent CDI requiring systemic antibiotics, SPV appeared safe and was associated with a clinically relevant reduction in recurrence, although the trial was underpowered. These findings support further adequately powered randomized studies to define the role of SPV in preventing CDI recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag032","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:48:27Z","timestamp":1772023707000},"source":"Crossref","is-referenced-by-count":2,"title":["Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of\n                    <i>clostridioides difficile<\/i>\n                    infection in patients receiving systemic antibiotic therapy (PREVAN trial)"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3446-1991","authenticated-orcid":false,"given":"Rafael","family":"San-Juan","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"School of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-0363","authenticated-orcid":false,"given":"Julia","family":"Orig\u00fcen","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Cl\u00ednico Universitario Lozano Blesa, IIS ARAG\u00d3N , Zaragoza ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-8001","authenticated-orcid":false,"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"School of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-512X","authenticated-orcid":false,"given":"Karen","family":"Campion","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Tiago","family":"Silva","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"School of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5333-7529","authenticated-orcid":false,"given":"Francisco","family":"L\u00f3pez-Medrano","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"School of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6629-6789","authenticated-orcid":false,"given":"Jennifer","family":"VILLA","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-4208","authenticated-orcid":false,"given":"Beatriz","family":"D\u00edaz-Pollan","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"Unit of Infectious Disease, Hospital Universitario La Paz, IdiPAZ (La Paz Institute for Health Research) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Callejas-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario Puerta de Hierro-Majadahonda , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Candela","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital Universitario Severo Ochoa , Legan\u00e9s, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-0819","authenticated-orcid":false,"given":"Jorge","family":"Boan","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1497-8770","authenticated-orcid":false,"given":"Eduardo","family":"Aparicio-Minguijon","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-2337","authenticated-orcid":false,"given":"Mar\u00eda Asunci\u00f3n","family":"P\u00e9rez-Jacoiste Asin","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"School of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rodriguez-Goncer","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"School of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00edn-Arriscado","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12), Spanish Clinical Research Network (SCReN), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5438-8093","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-8255","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201812 de Octubre\u2019, Instituto de Investigaci\u00f3n Hospital \u201812 de Octubre\u2019 (imas12) , Madrid ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII) , Madrid ,","place":["Spain"]},{"name":"School of Medicine, Universidad Complutense , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026073102212966700_dlag032-B1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"2026073102212966700_dlag032-B2","doi-asserted-by":"publisher","first-page":"16020","DOI":"10.1038\/nrdp.2016.20","article-title":"Clostridium difficile infection","volume":"2","author":"Smits","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026073102212966700_dlag032-B3","doi-asserted-by":"publisher","first-page":"18943","DOI":"10.2807\/ese.13.31.18943-en","article-title":"Increasing rates in Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999-2007","volume":"13","author":"Asensio","year":"2008","journal-title":"Euro Surveill"},{"key":"2026073102212966700_dlag032-B4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3201\/eid1203.051064","article-title":"Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003","volume":"12","author":"McDonald","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2026073102212966700_dlag032-B5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1128\/JCM.03352-12","article-title":"Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain","volume":"51","author":"Rodriguez-Pardo","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2026073102212966700_dlag032-B6","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1093\/cid\/cis356","article-title":"Predictors of first recurrence of Clostridium difficile infection: implications for initial management","volume":"55","author":"Eyre","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026073102212966700_dlag032-B7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1017\/ice.2014.88","article-title":"Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis","volume":"36","author":"Deshpande","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026073102212966700_dlag032-B8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10096-015-2549-9","article-title":"First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis","volume":"35","author":"Larrainzar-Coghen","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026073102212966700_dlag032-B9","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026073102212966700_dlag032-B10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026073102212966700_dlag032-B11","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/S1473-3099(22)00274-2","article-title":"How can patients with Clostridioides difficile infection on concomitant antibiotic treatment be best managed?","volume":"22","author":"Fitzpatrick","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026073102212966700_dlag032-B12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/ciy259","article-title":"Results from a randomized, placebo-controlled clinical trial of a RBX2660-A Microbiota-based drug for the prevention of recurrent Clostridium difficile infection","volume":"67","author":"Dubberke","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026073102212966700_dlag032-B13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"key":"2026073102212966700_dlag032-B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026073102212966700_dlag032-B15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/1471-2334-14-306","article-title":"Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study","volume":"14","author":"Zilberberg","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026073102212966700_dlag032-B16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.18433\/J32S41","article-title":"Identification of factors impacting recurrent Clostridium difficile infection and development of a risk evaluation tool","volume":"19","author":"Carpenter","year":"2016","journal-title":"J Pharm Pharm Sci"},{"key":"2026073102212966700_dlag032-B17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/ajg.2016.417","article-title":"Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections","volume":"111","author":"Carignan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026073102212966700_dlag032-B18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0897190019825994","article-title":"Long-term efficacy of oral vancomycin prophylaxis for the prevention of Clostridium difficile recurrence","volume":"33","author":"Knight","year":"2020","journal-title":"J Pharm Pract"},{"key":"2026073102212966700_dlag032-B19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/cid\/ciz966","article-title":"Effectiveness of oral vancomycin for prevention of healthcare facility-onset Clostridioides difficile infection in targeted patients during systemic antibiotic exposure","volume":"71","author":"Johnson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026073102212966700_dlag032-B20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/cid\/ciw401","article-title":"Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents","volume":"63","author":"Van Hise","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026073102212966700_dlag032-B21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1093\/cid\/ciy822","article-title":"Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients","volume":"68","author":"Ganetsky","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026073102212966700_dlag032-B22","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.bbmt.2019.06.021","article-title":"Oral vancomycin prophylaxis as secondary prevention against Costridioides difficile infection in the hematopoietic stem cell transplantation and hematologic malignancy population","volume":"25","author":"Morrisette","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026073102212966700_dlag032-B23","doi-asserted-by":"publisher","first-page":"e2020031807","DOI":"10.1542\/peds.2020-031807","article-title":"Oral vancomycin as secondary prophylaxis for Clostridioides difficile infection","volume":"148","author":"Bao","year":"2021","journal-title":"Pediatrics"},{"key":"2026073102212966700_dlag032-B24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1017\/ice.2020.176","article-title":"Oral vancomycin prophylaxis against recurrent Clostridioides difficile infection: efficacy and side effects in two hospitals","volume":"41","author":"Zacharioudakis","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026073102212966700_dlag032-B25","doi-asserted-by":"publisher","first-page":"1756284821994046","DOI":"10.1177\/1756284821994046","article-title":"Oral vancomycin prophylaxis for primary and secondary prevention of Clostridioides difficile infection: a systematic review and meta-analysis","volume":"14","author":"Tariq","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2026073102212966700_dlag032-B26","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1017\/ice.2020.277","article-title":"Oral vancomycin prophylaxis for the prevention of Clostridium difficile infection: A systematic review and meta-analysiseview and meta-analysis","volume":"41","author":"Babar","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026073102212966700_dlag032-B27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/antibiotics11020183","article-title":"Oral vancomycin prophylaxis for primary and secondary prevention of Clostridioides difficile infection in patients treated with systemic antibiotic therapy: a systematic review, meta-analysis and trial sequential analysis","volume":"11","author":"Maraolo","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026073102212966700_dlag032-B28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026073102212966700_dlag032-B29","doi-asserted-by":"publisher","first-page":"e072121","DOI":"10.1136\/bmjopen-2023-072121","article-title":"Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of Clostridioides difficile infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial","volume":"13","author":"San-Juan","year":"2023","journal-title":"BMJ Open"},{"key":"2026073102212966700_dlag032-B30","doi-asserted-by":"publisher","first-page":"e2517834","DOI":"10.1001\/jamanetworkopen.2025.17834","article-title":"Oral vancomycin for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial","volume":"8","author":"Keating","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026073102212966700_dlag032-B31","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J Antimicrob Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/2\/dlag032\/67278631\/dlag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/2\/dlag032\/67278631\/dlag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:21:33Z","timestamp":1785478893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag032\/8511966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag032","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,9]]},"article-number":"dlag032"}}